September 25, 2016 11:17 AM ET

Biotechnology

Company Overview of VBI Vaccines Inc. Prior to merger with SciVac Therapeutics Inc.

Key Executives for VBI Vaccines Inc. Prior to merger with SciVac Therapeutics Inc.

NameBoard RelationshipsTitleAge
Jeff R. Baxter FCMA24 RelationshipsChief Executive Officer, President and Director55
Francisco Diaz-Mitoma M.D., Ph.D.10 RelationshipsFounder--
James J. Martin CPA, MBA No RelationshipsChief Financial Officer49

VBI Vaccines Inc. Prior to merger with SciVac Therapeutics Inc. Board Members*

NameBoard RelationshipsPrimary CompanyAge
Steven S. Gillis M.D., Ph.D. 149 RelationshipsArch Venture Partners, L.P.62
Jeff R. Baxter FCMA 24 RelationshipsVBI Vaccines, Inc.55
Scott Requadt J.D., MBA 21 RelationshipsPhoenix Strategy Investments, LLC48
Alan P. Timmins 17 RelationshipsYamhill Valley Vineyards Inc.56
Stanley A. Plotkin M.D. 86 RelationshipsMymetics Corporation83
View All Board Members

VBI Vaccines Inc. Prior to merger with SciVac Therapeutics Inc. Executive Committees*

Committee NameChairpersonBoard RelationshipsMembers
Audit Committee Alan P. Timmins17 Relationships3 Executives
Compensation Committee J.D., MBAScott Requadt21 Relationships2 Executives
Nominating Committee M.D., Ph.D.Steven S. Gillis149 Relationships3 Executives
Corporate Governance Committee M.D., Ph.D.Steven S. Gillis149 Relationships3 Executives
View Committee Details
*Data is at least as current as the most recent Definitive Proxy.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

CEO COMPENSATION IN THIS INDUSTRY

  Industry Range
Salary$400.0K
400.0K
383.9K
Bonus$180.0K
180.0K
263.7K
Total Short Term Compensation
Not meaningful
Total Value of Options$580.0K
580.0K
33.7M
Compensation as of Fiscal Year 2015
VBI Vaccines Inc. Prior to merger with SciVac Therapeutics Inc. CEO Compensation
Industry Average

INDUSTRY EXECUTIVE CHANGES

GlycoMimetics, Inc. Announces the Intention of Franklin H. Top to Resign as Directors Effective January 1, 2017
September 23, 2016 1:31 PM ET
Symic Bio Appoints Thomas N. Wight to Scientific Advisory Board
September 23, 2016 12:01 PM ET
Momenta Pharmaceuticals Inc. Appoints Corey N. Fishman to its Board of Directors
September 23, 2016 12:00 PM ET
uniQure N.V. Announces Management and Board Changes
September 22, 2016 8:18 PM ET
Ligand Pharmaceuticals Incorporated Announces Change of Principal Accounting Officer
September 22, 2016 8:06 PM ET

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact VBI Vaccines Inc. Prior to merger with SciVac Therapeutics Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.